The FDA has cleared NuVasive's thoracolumbar interbody portfolio for the treatment of multilevel sagittal deformities.
The interbody line was previously approved for one- to two-level spine surgery, according to a Nov. 4 announcement from the spine device company.
The portfolio features the company's Cohere, Modulus, TLX, MLX and CoRoent implants, which are available in several dimensions to fit each patient's unique anatomy.
The implants can be integrated with NuVasive's Bendini spinal rod bending system and its surgical planning tools designed for improved sagittal alignment.